Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome

We present primary results from the phase 1b GO29754 study evaluating the safety and tolerability of atezolizumab, a programmed death-ligand 1 inhibitor, alone and in combination with azacitidine, a hypomethylating agent (HMA), in patients with relapsed/refractory (R/R) or HMA-naïve myelodysplastic...

Descripción completa

Detalles Bibliográficos
Autores principales: Gerds, Aaron T., Scott, Bart L., Greenberg, Peter, Lin, Tara L., Pollyea, Daniel A., Verma, Amit, Dail, Monique, Feng, Yuning, Green, Cherie, Ma, Connie, Medeiros, Bruno C., Yan, Mark, Yousefi, Kasra, Donnellan, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864663/
https://www.ncbi.nlm.nih.gov/pubmed/34932793
http://dx.doi.org/10.1182/bloodadvances.2021005240

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864663/
https://www.ncbi.nlm.nih.gov/pubmed/34932793
http://dx.doi.org/10.1182/bloodadvances.2021005240

Ejemplares similares